Adial Pharmaceuticals Announces Partnership With Catalent To Package And Distribute Adial’s AD04 For Its Phase 3 Trial




Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced a partnership with Catalent to advance clinical activities related to AD04, Adial’s genetically targeted, lead investigational new drug product for the treatment of alcohol use disorder. This partnership brings together critical capabilities to allow the commencement of Adial’s planned initial Phase 3 trial, with Catalent providing clinical packaging and distribution.

Learn More